402 related articles for article (PubMed ID: 9818851)
1. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.
Rinne UK; Larsen JP; Siden A; Worm-Petersen J
Neurology; 1998 Nov; 51(5):1309-14. PubMed ID: 9818851
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
[TBL] [Abstract][Full Text] [Related]
3. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
4. Clinical advantages of COMT inhibition with entacapone - a review.
Gordin A; Kaakkola S; Teräväinen H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
[TBL] [Abstract][Full Text] [Related]
5. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
Brooks DJ; Sagar H;
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1071-9. PubMed ID: 12876237
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
7. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.
Ruottinen HM; Rinne UK
J Neurol Neurosurg Psychiatry; 1996 Jan; 60(1):36-40. PubMed ID: 8558148
[TBL] [Abstract][Full Text] [Related]
8. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
[TBL] [Abstract][Full Text] [Related]
9. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
Larsen JP; Worm-Petersen J; Sidén A; Gordin A; Reinikainen K; Leinonen M;
Eur J Neurol; 2003 Mar; 10(2):137-46. PubMed ID: 12603288
[TBL] [Abstract][Full Text] [Related]
10. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
12. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
Kulisevsky J
Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622
[TBL] [Abstract][Full Text] [Related]
15. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
[TBL] [Abstract][Full Text] [Related]
17. Entacapone in the treatment of Parkinson's disease.
Schrag A
Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
[TBL] [Abstract][Full Text] [Related]
18. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
19. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Ruottinen HM; Rinne UK
Clin Neuropharmacol; 1996 Jun; 19(3):222-33. PubMed ID: 8726541
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.
Mizuno Y; Kanazawa I; Kuno S; Yanagisawa N; Yamamoto M; Kondo T
Mov Disord; 2007 Jan; 22(1):75-80. PubMed ID: 17094103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
